Assure Sets Record for Cash Collection and Procedures in Full-Year, Fourth Quarter 2020
DENVER, Jan. 11, 2021 Assure Holdings Corp. (the “
Company” or “
Assure”) (TSXV: IOM; OTCQB: ARHH), a provider of intraoperative neuromonitoring services (“
IONM”), announced an annual and quarterly record for cash collection and number of procedures in full-year and fourth quarter 2020.
John A. Farlinger, executive chairman and CEO said, “I am proud of the progress our billing and collections team has made and the success we have had in meeting our objectives in 2020. Since fully taking over the revenue cycle management function in February 2020 after our legacy 3
rd party billing provider was terminated due to poor performance, Assure invested heavily in this area by hiring a seasoned leader, staffing a 20-person internal billing and collections team and migrating to a platform that has an automated and integrated process, transitioning from what had historically been
Vodafone Group Plc's ("Vodafone") UK subsidiary, Vodafone Limited ("Vodafone UK") and Telefonica UK Limited ("TEF UK") (together, the "anchor tenants") today announce the commercialisation of Cornerstone Telecommunications Infrastructure Limited ("Cornerstone"), the 50:50 owned joint venture company that owns and manages their passive tower infrastructure in the United Kingdom.
Country Finance & Grants Manager reliefweb.int - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from reliefweb.int Daily Mail and Mail on Sunday newspapers.
In the news release, Hollister Biosciences Inc. Provides Update on Q4 2020 Performance Including CDN $14.93 Million in Revenue With an Estimated CDN $5.53 Million in EBITDA a YoY Revenue Increase of 3215% from Q4 2019, issued 07-Jan-2021 by Hollister Biosciences Inc. over CNW, we are advised by the company that the title should read “CDN $2.53 Million in EBITDA ” rather than “CDN $5.53 Million in EBITDA” as … In the news release, Hollister Biosciences Inc. Provides Update on Q4 2020 Performance Including CDN $14.93 Million in Revenue With an Estimated CDN $5.53 Million in EBITDA a YoY Revenue Increase of 3215% from Q4 2019, issued 07-Jan-2021 by Hollister Biosciences Inc. over CNW, we are advised by the company that the title should read “CDN $2.53 Million in EBITDA ” rather than “CDN $5.53 Million in EBITDA” as originally issued inadvertently. The complete, corrected release follows: